ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BPMC Blueprint Medicines Corporation

93.00
2.27 (2.50%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 725,963
Bid Price 88.22
Ask Price 96.64
News -
Day High 94.98

Low
43.89

52 Week Range

High
101.00

Day Low 90.47
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
2.27 2.50% 93.00 20:00:00
Open Price Low Price High Price Close Price Prev Close
92.76 90.47 94.98 93.00 90.73
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
13,733 725,963 $ 93.41 $ 67,811,310 - 43.89 - 101.00
Last Trade Time Type Quantity Stock Price Currency
19:13:59 9 $ 96.59 USD

Blueprint Medicines Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.69B 61.23M - 249.38M -506.98M -8.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BPMC Message Board. Create One! See More Posts on BPMC Message Board See More Message Board Posts

Historical BPMC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week88.0394.9884.6290.43746,4054.975.65%
1 Month95.0097.0084.3390.43608,295-2.00-2.11%
3 Months78.61101.0072.2488.47811,93714.3918.31%
6 Months48.48101.0047.6680.93831,86644.5291.83%
1 Year48.99101.0043.8969.67730,78444.0189.83%
3 Years98.00117.8637.8267.71650,103-5.00-5.10%
5 Years77.09125.6137.8272.01600,07915.9120.64%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Your Recent History

Delayed Upgrade Clock